Earnings Call · Q3 FY2024·2024-11-14

Q3 24EPS +37.50%·Rev n/aQ2 24EPS +27.84%·Rev n/aQ1 24EPS +28.10%·Rev n/aQ4 23EPS -6.67%·Rev n/a⚠ consensus missing

MiNK Therapeutics, Inc. INKT

Alexa Buffa — Corporate Communications

Jennifer Buell — Chief Executive Officer (CEO) or Senior Executive

Unidentified Company Representative — Company Representative (likely Senior Management)

Paul Ibbett — Executive or Senior Management (likely Chief Medical Officer or similar, given presentation of therapy)

Christine Klaskin — Chief Financial Officer (CFO) or Finance Executive

−5.6%1d on move date−4.9% vs SPY3d−12.5%5d−11.3%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more INKT calls or request research access.

More INKT calls Browse calls Request research access